Alkem Laboratories

₹5428.1 18.5 | 0.3%

WEBSITE BSE:539523 NSE : ALKEM 26 Dec, 16:01

Market Cap ₹64901 Cr.

Stock P/E 35.8

P/B 5.5

Current Price ₹5428.1

Book Value ₹ 984.5

Face Value 2

52W High ₹6440

Dividend Yield 0.74%

52W Low ₹ 4409.9

Edit Ratio

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Limited is a pharmaceutical agency. The Company is engaged inside the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates via 2 segments: pharmaceutical and investing. The Company produces generics,generic drugs, APIs and neutraceuticals, which it markets in India and about 50 international locations across the world. The Company offers numerous products, which include CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, amongst others. The Company has approximately 16 production facilities, of which 14 manufacturing facilities are at geographically different places in India and within the United States.

Alkem Laboratories Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Alkem Laboratories Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Alkem Laboratories Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Net Sales	2708	3138	3859	4548	5281	5714	6677	7220	8830	9055	9748
Other Income	169	182	251	117	101	68	96	190	200	266	306
Total Income	2878	3320	4110	4665	5382	5782	6773	7410	9030	9321	10054
Total Expenditure	2296	2792	3139	3670	4308	4668	5209	5271	7019	7678	7783
Operating Profit	582	528	971	995	1074	1113	1564	2139	2010	1643	2271
Interest	84	73	59	24	32	28	39	43	38	86	82
Depreciation	43	60	74	76	108	141	187	199	219	230	244
Exceptional Income / Expenses	0	0	0	0	0	0	0	-13	0	0	-64
Profit Before Tax	455	395	839	894	934	944	1338	1884	1753	1327	1881
Provision for Tax	11	28	139	11	218	144	74	199	212	193	134
Profit After Tax	444	368	700	883	716	800	1264	1685	1541	1134	1747
Adjustments	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	444	368	700	883	716	800	1264	1685	1541	1134	1747
Adjusted Earnings Per Share	37.1	30.8	58.6	73.9	59.9	66.9	105.8	141	128.9	94.9	146.1

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	8%	11%	11%	14%
Operating Profit CAGR	38%	2%	15%	15%
PAT CAGR	54%	1%	17%	15%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	9%	16%	22%	NA%
ROE Average	18%	16%	19%	18%
ROCE Average	18%	16%	19%	18%

Alkem Laboratories Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	2790	3101	3600	4393	4885	5465	6280	7626	8744	9350	10555
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	54	28	0	0	6	6	6	0	0	0	0
Other Non-Current Liabilities	89	129	-341	-499	-442	-486	-580	-717	-747	-748	-910
Total Current Liabilities	1300	1603	1154	1413	1787	1670	2580	2910	4124	3045	3106
Total Liabilities	4232	4861	4413	5307	6236	6656	8287	9818	12120	11646	12751
Fixed Assets	839	870	875	1126	1471	1606	1837	1758	1882	1825	1782
Other Non-Current Assets	1185	2213	1459	1914	1733	1969	2221	2428	3378	3049	2929
Total Current Assets	2209	1777	2079	2266	3032	3063	4213	5626	6859	6772	8040
Total Assets	4232	4861	4413	5307	6236	6656	8287	9818	12120	11646	12751

Alkem Laboratories Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	29	17	25	7	20	5	161	21	15	82	5
Cash Flow from Operating Activities	106	242	630	499	318	745	682	1324	1299	1437	1687
Cash Flow from Investing Activities	37	-260	311	-362	-273	-313	-995	-1121	-1669	197	-866
Cash Flow from Financing Activities	-154	26	-958	-125	-60	-276	173	-209	437	-1711	-959
Net Cash Inflow / Outflow	-12	8	-18	13	-15	156	-141	-5	67	-77	-138
Closing Cash & Cash Equivalent	17	25	7	20	5	161	21	15	82	5	-133

Alkem Laboratories Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	37.14	30.76	58.57	73.87	59.88	66.9	105.77	140.95	128.92	94.9	146.14
CEPS(Rs)	40.72	35.75	64.72	80.27	68.88	78.7	121.39	157.59	147.24	114.12	166.58
DPS(Rs)	4	4	12.7	15	13	16	25	30	34	50	40
Book NAV/Share(Rs)	233.35	259.39	301.09	367.43	408.65	457.15	525.34	637.87	731.38	782.09	882.86
Core EBITDA Margin(%)	14.67	10.62	18.22	18.81	17.64	17.54	21.01	25.63	19.49	14.47	19.13
EBIT Margin(%)	19.17	14.38	22.72	19.67	17.52	16.31	19.71	25.35	19.28	14.85	19.11
Pre Tax Margin(%)	16.18	12.15	21.23	19.16	16.93	15.83	19.16	24.78	18.87	13.94	18.31
PAT Margin (%)	15.78	11.3	17.72	18.92	12.97	13.41	18.1	22.16	16.59	11.92	17.01
Cash Profit Margin (%)	17.3	13.13	19.58	20.56	14.92	15.78	20.78	24.78	18.95	14.34	19.39
ROA(%)	10.73	8.09	15.1	18.17	12.4	12.41	16.92	18.61	14.05	9.55	14.32
ROE(%)	17.2	12.48	20.9	22.1	15.43	15.45	21.53	24.23	18.83	12.54	17.56
ROCE(%)	14.66	11.77	21.94	21.01	18.97	17.05	20.46	23.43	17.96	13.17	17.86
Receivable days	38.83	37.68	39.51	43.54	49.89	56.37	65.89	74.69	65.31	67.82	62.57
Inventory Days	61.45	59.04	52.58	56.64	62.28	61.69	54.45	62.55	68.54	70.96	63.5
Payable days	85.83	97.81	115.79	146.12	157.84	144.19	128.24	139.56	124.97	118.55	148.05
PER(x)	0	0	23.33	29.87	33.02	26.18	22.02	19.67	28.06	35.81	33.8
Price/Book(x)	0	0	4.54	6.01	4.84	3.83	4.43	4.35	4.95	4.34	5.6
Dividend Yield(%)	0	0	0.93	0.68	0.66	0.91	1.07	1.08	0.94	1.47	0.81
EV/Net Sales(x)	0.03	0.16	4.2	5.84	4.53	3.68	4.24	4.54	4.89	4.37	6.05
EV/Core EBITDA(x)	0.13	0.93	16.68	26.7	22.25	18.91	18.09	15.34	21.49	24.09	25.96
Net Sales Growth(%)	16.35	15.85	22.98	17.87	16.11	8.2	16.85	8.13	22.3	2.55	7.66
EBIT Growth(%)	-8.44	-13.24	91.79	2.29	5.29	0.58	41.61	39.98	-7.05	-21.1	38.88
PAT Growth(%)	-10.49	-17.21	90.43	26.13	-18.95	11.73	58.08	33.27	-8.54	-26.39	54.01
EPS Growth(%)	-10.49	-17.2	90.43	26.13	-18.95	11.73	58.08	33.27	-8.54	-26.39	54.01
Debt/Equity(x)	0.34	0.36	0.11	0.08	0.11	0.09	0.19	0.17	0.26	0.12	0.09
Current Ratio(x)	1.7	1.11	1.8	1.6	1.7	1.83	1.63	1.93	1.66	2.22	2.59
Quick Ratio(x)	1.31	0.77	1.29	1	1.12	1.24	1.21	1.41	1.18	1.66	1.99
Interest Cover(x)	6.4	6.44	15.3	38.77	29.86	34.4	35.57	44.89	47.26	16.36	23.96
Total Debt/Mcap(x)	0	0	0.02	0.01	0.02	0.02	0.04	0.04	0.05	0.03	0.02

Alkem Laboratories Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	57.14	57.16	57.16	57.16	57.16	56.74	56.74	56.74	56.38	55.66
FII	5.67	4.46	4.41	4.44	5.64	6.03	8.49	9.11	8.69	9.02
DII	14.1	15.74	16.44	16.69	16.34	17.64	15.91	15.63	18.57	19.21
Public	23.09	22.65	21.99	21.7	20.86	19.59	18.86	18.52	16.36	16.1
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	6.83	6.83	6.83	6.83	6.83	6.78	6.78	6.78	6.74	6.66
FII	0.68	0.53	0.53	0.53	0.67	0.72	1.01	1.09	1.04	1.08
DII	1.69	1.88	1.97	2	1.95	2.11	1.9	1.87	2.22	2.3
Public	2.76	2.71	2.63	2.59	2.49	2.34	2.26	2.21	1.96	1.93
Others	0	0	0	0	0	0	0	0	0	0
Total	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96

Pros

Company is almost debt free.

Cons

Debtor days have increased from 118.55 to 148.05days.
Stock is trading at 5.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alkem Laboratories News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Alkem Laboratories

Add Watchlist

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Share Price

Alert Data

Quarterly Price

Peer Comparison

Alkem Laboratories Quarterly Results

Alkem Laboratories Profit & Loss

Growth Rates

Alkem Laboratories Balance Sheet

Alkem Laboratories Cash Flow

Alkem Laboratories Ratios

Alkem Laboratories Shareholding Pattern

Alkem Laboratories News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!